

























![]()
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy June 16, 2026 8:30 AM EDT
Company Participants
Michael Nofi - Chief Financial Officer
Kevin Koch - President, CEO & Director
Aylin Tugcu
Conference Call Participants
Michael Ayers
Anjali Owens
Jenny Gonzalez-Armenta
Tessa Romero - JPMorgan Chase & Co, Research Division
Yasmeen Rahimi - Piper Sandler & Co., Research Division
Joshua Yan - Raymond James & Associates, Inc., Research Division
Adithya Jayaraman - Evercore Inc.
Laura Chico - Wedbush Securities Inc., Research Division
Debjit Chattopadhyay - Guggenheim Securities, LLC, Research Division
Srikripa Devarakonda - Truist Securities, Inc., Research Division
Lander Egaña-Gorroño - H.C. Wainwright & Co, LLC, Research Division
Kyuwon Choi - Goldman Sachs Group, Inc., Research Division
Presentation
Operator
Hello, and welcome to the Edgewise Therapeutics Update Call. [Operator Instructions] As a reminder, this conference is being recorded today. If you have any objections, please disconnect at this time. I would now like to pass the call over to Michael Nofi, Edgewise CFO. Please proceed.
Michael Nofi
Chief Financial Officer
Thank you, and good morning. Welcome to the Edgewise Therapeutics conference call to discuss our top line data of EDGE-7500 from the Phase II CIRRUS-HCM Part D 12-week trial in individuals with obstructive and nonobstructive hypertrophic cardiomyopathy. This morning, we issued a press release, which outlines these results. You can access the press release as well as the slides that we will be presenting today by going to the Investors and News section of our website at www.edgewisetx.com. A replay of the event will also be available as a webcast on our website.
Joining me today are Dr. Kevin Koch, Chief Executive Officer; Dr. Behrad Derakhshan, Chief Operating Officer; Dr. Aylin Tugcu, Senior Vice President, Cardiovascular Clinical Development and Medical Affairs; Dr. Michael Ayers, Director of the HCM Center of Excellence at the University of Virginia and EDGE-7500 Clinical Program Lead; and Dr. Chris Duton, Senior Vice President, Cardiovascular
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。